nomifensine has been researched along with Paranoia in 3 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katona, C | 1 |
| Cohen, SI | 1 |
| Overall, JE | 1 |
1 trial available for nomifensine and Paranoia
| Article | Year |
|---|---|
Efficacy of nomifensine in different depressive syndromes.
Topics: Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Humans; Isoqu | 1984 |
2 other studies available for nomifensine and Paranoia
| Article | Year |
|---|---|
Paranoid symptoms after nomifensine.
Topics: Adult; Depression; Goiter; Humans; Isoquinolines; Male; Nomifensine; Paranoid Disorders | 1982 |
Paranoid symptoms after nomifensine.
Topics: Humans; Hyperthyroidism; Isoquinolines; Nomifensine; Paranoid Disorders | 1982 |